Attenuated DNA damage repair delays therapy-related myeloid neoplasms in a mouse model

Cell Death and Disease

Volumn 7, Issue 10, 2016, Pages

  Tong, Kit I ^a   Ota, Kazushige ^b   Komuro, Akiyoshi ^b   Ueda, Takeshi ^b   Ito, Akihiko ^b   Anne Koch, C ^a,c   Okada, Hitoshi ^a,b,c,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

^d KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIS PROTEIN; DNA LIGASE; DNA LIGASE 4; DNA PK PROTEIN; GAMMA H2AX; HISTONE H2AX; IMMUNOGLOBULIN HEAVY CHAIN; KU ANTIGEN; KU80 PROTEIN; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; XRCC4 PROTEIN; APRATAXIN-AND-PNK-LIKE FACTOR, MOUSE; CARRIER PROTEIN; SMALL INTERFERING RNA;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; BONE MARROW; CELL CYCLE ARREST; CELL DEATH; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; EMBRYO; ERYTHROBLAST; FIBROBLAST; G2 PHASE CELL CYCLE CHECKPOINT; GENE CLUSTER; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MEGAKARYOCYTE; METAPHASE; MOUSE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RADIATION EXPOSURE; SENESCENCE; SIGNAL TRANSDUCTION; SPLEEN CELL; THYMOCYTE; VDJ RECOMBINATION; WHOLE BODY RADIATION; ANIMAL; BONE MARROW CANCER; CELL CLONE; CELL DIVISION; CHROMOSOME; DISEASE MODEL; GENE SILENCING; GENE TRANSLOCATION; IONIZING RADIATION; METABOLISM; ONCOGENE; PATHOLOGY; RADIATION RESPONSE;

ANIMALS; BONE MARROW; BONE MARROW NEOPLASMS; CARRIER PROTEINS; CELL DEATH; CELL DIVISION; CHROMOSOME ABERRATIONS; CHROMOSOMES, MAMMALIAN; CLONE CELLS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA END-JOINING REPAIR; DNA REPAIR; GENE KNOCKDOWN TECHNIQUES; HEMATOPOIESIS; HUMANS; MICE; ONCOGENES; RADIATION, IONIZING; RNA, SMALL INTERFERING; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84990197359     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.298     Document Type: Article

References (47)

1. Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013; 10: 289-301.
2. Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol 2009; 132: 410-425.
3. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15-25.
4. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015; 518: 552-555.
5. Rooney S, Chaudhuri J, Alt FW. The role of the non-homologous end-joining pathway in lymphocyte development. Immunol Rev 2004; 200: 115-131.
6. Deriano L, Roth DB. Modernizing the non-homologous end-joining repertoire: alternative and classical NHEJ share the stage. Annu Rev Genet 2013; 47: 433-544.
7. Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, Murphy M et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 2007; 449: 478-482.
8. Ahel I, Ahel D, Matsusaka T, Clark AJ, Pines J, Boulton SJ et al. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 2008; 451: 81-85.
9. Macrae CJ, McCulloch RD, Ylanko J, Durocher D, Koch CA. APLF (C2orf13) facilitates nonhomologous end-joining and undergoes ATM-dependent hyperphosphorylation following ionizing radiation. DNA Repair (Amst) 2008; 7: 292-302.
10. Rulten SL, Fisher AE, Robert I, Zuma MC, Rouleau M, Ju L et al. PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol Cell 2011; 41: 33-45.
11. Fenton AL, Shirodkar P, Macrae CJ, Meng L, Koch CA. The PARP3-and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair. Nucl Acids Res 2013; 41: 4080-4092.
12. Shirodkar P, Fenton AL, Li M, Koch CA. Identification and functional characterization of a kubinding motif in Aprataxin Polynucleotide Kinase/Phosphatase-like Factor (APLF). J Biol Chem 2013; 288: 19604-19613.
13. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002; 109: S45-S55.
14. Chaudhuri J, Basu U, Zarrin A, Yan C, Franco S, Perlot T et al. Evolution of the immunoglobulin heavy chain class switch recombination. Adv Immunol 2007; 94: 157-214.
15. Rooney S, Sekiguchi J, Zhu C, Cheng HL, Manis J, Whitlow S et al. Leaky Scid phenotype associated with defective V(D)J coding end and processing in Artemis-deficient mice. Mol Cell 2002; 10: 1379-1390.
16. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
17. Reinhardt HC, Schemacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012; 28: 128-136.
18. Mukherjee B, Kessinger C, Kobayashi J, Chen BP, Chen DJ, Chatterjee A et al. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair 2006; 5: 575-590.
19. Blankenbecler R. Low-dose pretreatment for radiation therapy. Dose Response 2010; 8: 534-542.
20. Shadley JD, Dai G. Cytogenetic and survival adaptive responses in G1 phase human lymphocytes. Mutat Res 1992; 265: 273-281.
21. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002; 100: 238-245.
22. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
23. Petrini M, Felicetti F, Bottero L, Errico MC, Morsilli O, Boe A et al. HOXB1 restored expression promotes apoptosis and differentiation in the HL60 leukemic cell line. Cancer Cell Int 2013; 13: 101.
24. Yan-Fang T, Dong W, Li P, Wen-Li Z, Jun L, Na W et al. Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays. Cancer Cell Int 2012; 12: 40.
25. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARa gene in acute promyelocytic leukemia. Oncogene 2001; 20: 7186-7203.
26. Diaz MO, Le Beau MM, Pitha P, Rowley JD. Interferon and c-ets-1 genes in the translocation (9;11)(p22;q23) in human acute monocytic leukemia. Science 1986; 231: 265-267.
27. Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 2002; 109: 811-821.
28. Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett Y, Difilippantonio S et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008; 135: 1028-1038.
29. Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer 2013; 13: 443-454.
30. Chiang C, Jacobsen JC, Ernst C, Hanscom C, Heilbut A, Blumenthal I et al. Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. Nat Genet 2012; 44: 390-397.
31. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
32. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
33. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.
34. Ferguson DO, Sekiguchi JM, Chang S, Frank KM, Gao Y, DePinho RA et al. The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc Natl Acad Sci USA 2000; 97: 6630-6633.
35. Difilippantonio MJ, Petersen S, Chen HT, Johnson R, Jasin M, Kanaar R et al. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med 2002; 196: 469-480.
36. Simsek D, Jasin M. Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nat Struct Mol Biol 2010; 17: 410-416.
37. Zhang Y, Jasin M. An essential role for CtIP in chromosomal translocation formation through an alternative endjoining pathway. Nat Struct Mol Biol 2011; 18: 80-84.
38. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clini Oncol 2001; 19: 1405-1413.
39. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20: 1943-1949.
40. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269-1283.
41. Chao C, Herr D, Chun J, Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 2006; 25: 2615-2622.
42. Armata HL, Garlick DS, Sluss HK. The ataxia-telangiectasia-mutated target site Ser18 is required for p53-meidated tumor suppression. Cancer Res 2007; 67: 11696-11703.
43. Gudkov AV, Komarova EA. Dangerous habits of a security guard: the two faces of p53 as a drug target. Human Molecular Genetics 2007; 16: R67-R72.
44. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998; 280: 1089-1091.
45. Ehrenstein MR, Rada C, Jones AM, Milstein C, Neuberger MS. Switch junction sequences in PMS2-deficient mice reveal a microhomology-mediated mechanism of Ig class switch recombination. Proc Natl Acad Sci USA 2001; 98: 14553-14558.
46. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V. DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci USA 2004; 101: 7624-7629.
47. Kataoka Y, Bindokas VP, Duggan RC, Murley JS, Grdina DJ. Flow cytometric analysis of phosphorylated histone H2AX following exposure to ionizing radiation in human microvascular endothelial cells. J Radiat Res 2006; 47: 245-257.